CompetitorsNarrow moat

AbbVie (ABBV) — moat facet

AbbVie's main immunology rival also shares its cancer drug's profits, and in obesity AbbVie is the one arriving late.

AbbVie's annual report names drug classes rather than companies as competitors. Its immunology products compete with IL-23 inhibitors, IL-17 inhibitors, JAK inhibitors and biosimilars; its oncology products with BTK inhibitors, antibody-drug conjugates and cell therapies1; and a number of other companies market products positioned as competitors to Botox2. It also says it has no single customer whose loss would have a material adverse effect3.

Competitors by kindPartner and rivalJohnson & Johnson (Imbruvica profit share; Tremfya)Generic challengersUbrelvy and Qulipta patent suitsToxin rivalsproducts positioned against BotoxObesity leadersAbbVie enters with a $350M licenceImmunology growth, Q2 202615.1%AbbVie 10-K FY2025, Q2 2026 10-Q and release; Q4 2025 call
Four kinds of rival.

The rivals that matter are four different kinds of relationship. Johnson & Johnson is both a partner, sharing Imbruvica's international profits4, and the main rival to Skyrizi through Tremfya5. The generic makers challenging AbbVie's migraine patents are rivals that wait for the law to let them in6. The other toxin makers compete with Botox where patients pay themselves. And in obesity, AbbVie is the challenger entering a market others already lead, with an early-stage amylin programme licensed for $350 million upfront7.

Competition in this industry is decided mostly by patents and payers rather than by price wars between originators. The Skyrizi versus Tremfya contest is the exception, and it is being fought on clinical data and on the benefit managers' formularies.

The contest also runs through the benefit managers. AbbVie's rebates to managed care were $22,307 million in 20258, much of it paid to secure preferred placement against competing drugs. When a rival offers a larger rebate, the formulary can change without any doctor preferring the rival's drug. That is why competition in this industry often looks like negotiation rather than rivalry.

The moat's competitive test is the immunology growth rate. Immunology grew 15.1% to $8,786 million in the second quarter of 20269; growth falling below the market's while Tremfya accelerates would say AbbVie is losing the next generation of patients.

Moat trajectory: Holding steady

Immunology still growing 15%; generic challenges filed on migraine drugs.

The number that tests this moat
Reported
Immunology revenue, latest quarter
$8,786M, +15.1% (Q2 2026)

The franchise against its rivals; growth below the market's would mean the next patients are going elsewhere.

Source: AbbVie Q2 2026 results release ↗
Dig deeper
DIG DEEPER 01
Johnson & Johnson: Partner on Imbruvica, Rival in IL-23
Johnson & Johnson shares Imbruvica's profits with AbbVie abroad and fights it for every new bowel-disease patient at home.
DIG DEEPER 02
The Generic Makers Waiting at the Patent Line
At least nine generic makers are already in court over AbbVie's two migraine drugs.
DIG DEEPER 03
The Other Toxins
Rival toxins have already taken share from Botox Cosmetic in America, where patients pay for themselves.
DIG DEEPER 04
Obesity: Arriving After the Leaders
In obesity, the fastest-growing drug market, AbbVie is a latecomer with a $350 million licence.
References
  1. ReportedIts immunology products compete with IL-23 inhibitors, IL-17 inhibitors, JAK inhibitors and biosimilars; its oncology products with BTK inhibitors, antibody-drug conjugates and cell therapies; and a number of other companies market products positioned as competitors to Botox.
    AbbVie Form 10-K for fiscal 2025 - Item 7 MD&A: net revenues by product and region, and rebates. — FY2025 · publ. 20 February 2026 · source ↗
  2. ReportedIts immunology products compete with IL-23 inhibitors, IL-17 inhibitors, JAK inhibitors and biosimilars; its oncology products with BTK inhibitors, antibody-drug conjugates and cell therapies; and a number of other companies market products positioned as competitors to Botox.
    AbbVie Form 10-K for fiscal 2025 - Item 7 MD&A: net revenues by product and region, and rebates. — FY2025 · publ. 20 February 2026 · source ↗
  3. ReportedIt also says it has no single customer whose loss would have a material adverse effect.
    AbbVie Form 10-K for fiscal 2025 - Item 1 business: products, customers, competition and research. — FY2025 · publ. 20 February 2026 · source ↗
  4. ReportedJohnson & Johnson is both a partner, sharing Imbruvica's international profits, and the main rival to Skyrizi through Tremfya.
    AbbVie second-quarter 2026 results release, Form 8-K exhibit 99.1. — Q2 2026 · publ. 31 July 2026 · source ↗
  5. ReportedJohnson & Johnson is both a partner, sharing Imbruvica's international profits, and the main rival to Skyrizi through Tremfya.
    The Motley Fool, AbbVie Q4 2025 earnings call transcript - 2026 revenue assumptions by product and management's comments on share and competitors. — Q4 2025 · publ. 4 February 2026 · source ↗
  6. ReportedThe generic makers challenging AbbVie's migraine patents are rivals that wait for the law to let them in.
    AbbVie Form 10-Q for the quarter ended 30 June 2026 - product revenue, the balance sheet, cash flow and the Apogee agreement. — Q2 2026 · publ. 3 August 2026 · source ↗
  7. ReportedAnd in obesity, AbbVie is the challenger entering a market others already lead, with an early-stage amylin programme licensed for $350 million upfront.
    AbbVie Form 10-K for fiscal 2025 - financial statements and notes: earnings, cash flow, balance sheet, acquisitions and contingent consideration. — FY2025 · publ. 20 February 2026 · source ↗
  8. ReportedAbbVie's rebates to managed care were $22,307 million in 2025, much of it paid to secure preferred placement against competing drugs.
    AbbVie Form 10-K for fiscal 2025 - Item 7 MD&A: net revenues by product and region, and rebates. — FY2025 · publ. 20 February 2026 · source ↗
  9. ReportedImmunology grew 15.1% to $8,786 million in the second quarter of 2026; growth falling below the market's while Tremfya accelerates would say AbbVie is losing the next generation of patients.
    AbbVie second-quarter 2026 results release, Form 8-K exhibit 99.1. — Q2 2026 · publ. 31 July 2026 · source ↗
Sources
Generated September 25, 2026